Literature DB >> 19074973

Regulation of drug transporter expression in human hepatocytes exposed to the proinflammatory cytokines tumor necrosis factor-alpha or interleukin-6.

Marc Le Vee1, Valérie Lecureur, Bruno Stieger, Olivier Fardel.   

Abstract

Tumor necrosis factor (TNF)-alpha and interleukin (IL)-6 are proinflammatory cytokines known to alter expression of drug transporters in rodent liver. However, their effects toward human hepatic transporters remain poorly characterized. Therefore, this study was designed to analyze the effects of these cytokines on drug transporter expression in primary human hepatocytes. Exposure to 100 ng/ml TNF-alpha or 10 ng/ml IL-6 for 48 h was found to down-regulate mRNA levels of major sinusoidal influx transporters, including sodium-taurocholate cotransporting polypeptide (NTCP), organic anion-transporting polypeptide (OATP) 1B1, OATP1B3, OATP2B1, organic cation transporter (OCT) 1, and organic anion transporter 2. TNF-alpha and IL-6 concomitantly reduced NTCP and OATP1B1 protein expression and NTCP, OATP, and OCT1 transport activities. IL-6, but not TNF-alpha, was also found to decrease mRNA expression of the canalicular transporters multidrug resistance 1 gene, multidrug resistance gene-associated protein (MRP) 2, and breast cancer resistance protein (BCRP); it concomitantly decreased MRP2 and BCRP protein expression. TNF-alpha, unlike IL-6, markedly reduced bile salt export pump mRNA levels and increased BCRP protein expression. Expression of the sinusoidal MRP3 efflux pump was found to be up-regulated at protein level by both TNF-alpha and IL-6. Taken together, these data show that TNF-alpha and IL-6 similarly altered expression of sinusoidal drug transporters and rather differentially that of canalicular efflux transporters. Such pronounced changes in hepatic transporter expression are likely to contribute to both cholestasis and alterations of pharmacokinetics caused by inflammation in humans.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19074973     DOI: 10.1124/dmd.108.023630

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  63 in total

1.  Obesity and its impact on drug therapy: are we ready for this change?

Authors:  Michael Neely; Stan Louie
Journal:  Clin Pharmacokinet       Date:  2011-12-01       Impact factor: 6.447

Review 2.  Drug transporters in tissues and cells relevant to sexual transmission of HIV: Implications for drug delivery.

Authors:  Minlu Hu; Sravan Kumar Patel; Tian Zhou; Lisa C Rohan
Journal:  J Control Release       Date:  2015-08-13       Impact factor: 9.776

Review 3.  Altered Transport and Metabolism of Phenolic Compounds in Obesity and Diabetes: Implications for Functional Food Development and Assessment.

Authors:  Benjamin W Redan; Kimberly K Buhman; Janet A Novotny; Mario G Ferruzzi
Journal:  Adv Nutr       Date:  2016-11-15       Impact factor: 8.701

4.  Predictive Value of Clinical Findings and Plasma Biomarkers after Fourteen Days of Prednisone Treatment for Acute Graft-versus-host Disease.

Authors:  George B McDonald; Laura Tabellini; Barry E Storer; Paul J Martin; Richard L Lawler; Steven L Rosinski; H Gary Schoch; John A Hansen
Journal:  Biol Blood Marrow Transplant       Date:  2017-05-03       Impact factor: 5.742

Review 5.  Pharmacokinetics, pharmacodynamics and physiologically-based pharmacokinetic modelling of monoclonal antibodies.

Authors:  Miroslav Dostalek; Iain Gardner; Brian M Gurbaxani; Rachel H Rose; Manoranjenni Chetty
Journal:  Clin Pharmacokinet       Date:  2013-02       Impact factor: 6.447

6.  Comment on the article "physiologically based modeling of pravastatin transporter-mediated hepatobiliary disposition and drug-drug interactions".

Authors:  Sibylle Neuhoff; Geoff T Tucker
Journal:  Pharm Res       Date:  2013-03-16       Impact factor: 4.200

7.  Altered Expression of Small Intestinal Drug Transporters and Hepatic Metabolic Enzymes in a Mouse Model of Familial Alzheimer's Disease.

Authors:  Yijun Pan; Kotaro Omori; Izna Ali; Masanori Tachikawa; Tetsuya Terasaki; Kim L R Brouwer; Joseph A Nicolazzo
Journal:  Mol Pharm       Date:  2018-08-22       Impact factor: 4.939

8.  Renal xenobiotic transporter expression is altered in multiple experimental models of nonalcoholic steatohepatitis.

Authors:  Mark J Canet; Rhiannon N Hardwick; April D Lake; Anika L Dzierlenga; John D Clarke; Michael J Goedken; Nathan J Cherrington
Journal:  Drug Metab Dispos       Date:  2014-12-08       Impact factor: 3.922

9.  Induction of hepatic multidrug resistance-associated protein 3 by ethynylestradiol is independent of cholestasis and mediated by estrogen receptor.

Authors:  María L Ruiz; Juan P Rigalli; Agostina Arias; Silvina Villanueva; Claudia Banchio; Mary Vore; Aldo D Mottino; Viviana A Catania
Journal:  Drug Metab Dispos       Date:  2012-10-17       Impact factor: 3.922

10.  Association of the TNF-{alpha}-C-857T polymorphism with resistance to the cholesterol-lowering effect of HMG-CoA reductase inhibitors in type 2 diabetic subjects.

Authors:  Toru Takahashi; Kazuma Takahashi; Mitsuhiro Yamashina; Chihaya Maesawa; Takashi Kajiwara; Haruhito Taneichi; Noriko Takebe; Yoshihito Kaneko; Tomoyuki Masuda; Jo Satoh
Journal:  Diabetes Care       Date:  2009-12-10       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.